(Q44454015)

3 December 2017

title

Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma (English)

1 reference

3 December 2017

Petri Bono

1

1 reference

3 December 2017

Lasse Teerenhovi

series ordinal

2

1 reference

3 December 2017

Heikki Joensuu

series ordinal

3

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

3 December 2017

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

3 December 2017

volume

97

1 reference

3 December 2017

issue

11

1 reference

3 December 2017

page(s)

2767-2775

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Tumor invasion and metastases: biochemical mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Vascular-specific growth factors and blood vessel formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Clinical implications of circulating angiogenic factors in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Circulating angiogenesis regulators in cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Endostatin: are the 2 years up yet?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Serum endostatin levels are elevated in patients with soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Secreted cathepsin L generates endostatin from collagen XVIII

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Alpha 1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Serum endostatin correlates with progression and prognosis of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Release of different fractions of epidermal growth factor from human platelets in vitro: preferential release of 140 kDa fraction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Release of platelet-derived growth factor from human platelets by arachidonic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11399

7 January 2021

Identifiers

DOI

10.1002/CNCR.11399

1 reference

3 December 2017

1 reference